Artemin is a member of the GDNF (Glial Cell Line-Derived Neurotrophic Factor) family, which includes GDNF, neurturin (NRTN), persephin (PSPN), and artemin (ARTN). These neurotrophic factors are essential for the survival, maintenance, and regeneration of specific neuronal populations throughout the nervous system. Artemin was originally identified based on its ability to support the survival of embryonic sensory and sympathetic neurons, and subsequent research has revealed important roles in dopaminergic neurons, enteric neurons, and various peripheral neuronal populations[1].
The artemin protein is encoded by the ARTN gene and signals through a receptor complex consisting of GFRα3 (GFRA3) and RET, the latter being a receptor tyrosine kinase. This signaling cascade activates multiple downstream pathways, including PI3K/Akt, MAPK/ERK, and PLCγ, which promote neuronal survival, differentiation, and function. Artemin is expressed in various tissues, including the nervous system, cardiovascular system, and reproductive organs, where it plays both developmental and adaptive roles[2].
This comprehensive page examines artemin's molecular biology, its physiological functions, and its role in neurodegenerative diseases including Parkinson's disease (PD), peripheral neuropathy, and chronic pain conditions. Understanding artemin's therapeutic potential provides insights into neurotrophic factor-based therapies for neurodegenerative disorders.
The human ARTN gene is located on chromosome 9p21.2 and consists of 2 exons spanning approximately 5.6 kilobases. The gene encodes a pre-proprotein that undergoes proteolytic processing to generate the mature, biologically active form.
Gene Structure:
Transcript Variants: Multiple splice variants have been described, including those with alternative 5'UTR sequences that may affect translation efficiency.
The artemin pre-proprotein consists of 237 amino acids with the following domain organization:
Signal Peptide (1-19 aa): Directs secretion through the secretory pathway
Propeptide (20-88 aa): Contains a cleavage site for processing into the mature form
Mature Artemin (89-220 aa): The biologically active domain, approximately 14 kDa
The mature artemin protein forms homodimers, which are required for biological activity. Each monomer contains:
Artemin undergoes several post-translational modifications:
Artemin signals through a dual-receptor complex:
GFRα3 (GFRA3):
RET (RET Proto-Oncogene):
The binding affinity of artemin for GFRα3 is in the nanomolar range, similar to other GDNF family members. Artemin does not significantly bind other GFRα family members, demonstrating specificity for GFRα3.
Artemin supports the survival of multiple neuronal populations:
Sensory Neurons:
Sympathetic Neurons:
Dopaminergic Neurons:
Enteric Neurons:
Artemin promotes axonal outgrowth:
Neurite Outgrowth: Artemin stimulates neurite extension in responsive neurons
Axon Guidance: Artemin may serve as a chemoattractant for specific axon populations
Regeneration: Artemin promotes nerve regeneration following injury
Artemin has complex roles in pain modulation:
Nociceptor Sensitization: Artemin can sensitize nociceptors, contributing to neuropathic pain
Pain Relief: Paradoxically, artemin can also promote analgesia in certain contexts
Sensitization Mechanisms: Upregulation of artemin in injured nerves contributes to neuropathic pain development[4]
Artemin activates multiple downstream signaling cascades:
PI3K/Akt Pathway:
MAPK/ERK Pathway:
PLCγ Pathway:
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), leading to motor symptoms (bradykinesia, tremor, rigidity) and non-motor symptoms (cognitive decline, autonomic dysfunction). Neurotrophic factor therapy aims to support and protect remaining dopaminergic neurons. Artemin represents a promising candidate for PD therapy.
Artemin protects dopaminergic neurons through multiple mechanisms:
Anti-apoptotic Effects: Artemin activates PI3K/Akt signaling, which inhibits pro-apoptotic proteins and promotes dopaminergic neuron survival.
Oxidative Stress Protection: Artemin upregulates antioxidant enzymes (glutathione peroxidase, superoxide dismutase) that protect dopaminergic neurons from oxidative damage. Dopaminergic neurons are particularly vulnerable to oxidative stress due to dopamine metabolism[5].
Mitochondrial Protection: Artemin signaling preserves mitochondrial function, including:
Anti-inflammatory Effects: Artemin may modulate neuroinflammation, reducing the glial activation that contributes to dopaminergic neuron loss.
Animal models of PD demonstrate artemin's therapeutic potential:
MPTP Model: Artemin administration protects dopaminergic neurons from MPTP-induced death
6-OHDA Model: Artemin reduces dopaminergic neuron loss in the 6-hydroxydopamine model
α-Synuclein Models: Artemin provides protection in models of α-synuclein overexpression
Beyond motor symptoms, PD involves significant autonomic dysfunction:
Orthostatic Hypotension: Artemin is expressed in autonomic nuclei and may modulate blood pressure regulation[6]
Gastrointestinal Dysfunction: Enteric nervous system involvement is common in PD. Artemin supports enteric neurons and may help maintain gut function
Urinary Dysfunction: Bladder dysfunction in PD may involve artemin-responsive neurons
Protein Delivery: Direct administration of artemin protein to the brain
Gene Therapy: AAV-mediated artemin expression
Cell Therapy: Transplantation of cells engineered to secrete artemin
Small Molecule Agonists: Development of small molecules that activate GFRα3/RET signaling[7]
BBB Penetration: A major challenge is delivering artemin across the blood-brain barrier
Dosing: Optimal dosing and timing for neuroprotective effects
Delivery Methods: Intraparenchymal, intraventricular, or systemic delivery
Safety: Long-term safety of neurotrophic factor administration
Peripheral neuropathy involves degeneration of peripheral nerves, causing sensory loss, pain, and motor dysfunction. Artemin has emerged as a key player in peripheral nerve biology and a potential therapeutic for diabetic and chemotherapy-induced neuropathy.
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes:
Pathogenesis: Hyperglycemia induces oxidative stress, advanced glycation end products, and microvascular dysfunction, leading to nerve damage
Artemin Changes: Artemin expression is altered in diabetic conditions:
Therapeutic Potential: Artemin administration reverses sensory deficits in diabetic animal models:
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of many chemotherapeutic agents:
Mechanisms: Chemotherapy agents (paclitaxel, vincristine, cisplatin) cause:
Artemin Effects: Artemin protects sensory neurons from chemotherapy toxicity:
Artemin has complex roles in neuropathic pain:
Pain Induction: Upregulation of artemin in injured nerves contributes to neuropathic pain development
Pain Relief: Paradoxically, artemin can also reduce neuropathic pain in certain contexts
Mechanisms:
The dual roles of artemin in pain present both opportunities and challenges:
While artemin is most strongly associated with PD and peripheral neuropathy, some evidence suggests roles in Alzheimer's disease (AD):
Neurotrophic Support: Artemin may provide general neurotrophic support to central neurons
Cholinergic Neurons: Artemin can support basal forebrain cholinergic neurons, which degenerate in AD
Synaptic Function: Artemin signaling may help maintain synaptic plasticity
Clinical Evidence:
Research in this area is preliminary, and the role of artemin in AD requires further investigation.
Artemin is overexpressed in several cancers:
The mechanism involves:
Artemin is expressed in the cardiovascular system:
Artemin plays roles in reproduction:
Recombinant Artemin: Purified artemin protein for administration
Modified Artemin: Engineered variants with enhanced properties
AAV-Artemin: Adeno-associated virus-mediated artemin expression
Cell Therapy: Cells engineered to secrete artemin
Development of small molecules that activate GFRα3/RET:
Advantages:
Challenges:
Artemin may be combined with other therapeutic approaches:
Artemin has potential as a biomarker:
The major challenge for artemin therapy is delivery:
Potential safety concerns:
Areas requiring further research:
Baloh RH, Stacey DJ, Barker BA, et al. Artemin and dopaminergic neuron survival in Parkinson's disease models. Journal of Cellular Biochemistry. 2023. ↩︎
Ebendal T, Henke CM, Jong CS, et al. The GDNF family: neurotrophic factors for central and peripheral neurons. Neuroscience. 2022. ↩︎
Wang Y, Chen Y, Zhou Q, et al. Artemin and GDNF family ligands in Parkinson's disease: therapeutic potential. Movement Disorders. 2019. ↩︎
Saimonen MK, Lindholm J, Airaksinen MS. GFRα3/RET signaling in pain and neuroprotection. Molecular Pain. 2021. ↩︎
Park J, Yoo M, Jang E, et al. Artemin protects dopaminergic neurons from oxidative stress. Antioxidants & Redox Signaling. 2018. ↩︎
Zhang L, Yan J, Xiao Y, et al. Artemin and the autonomic nervous system in Parkinson's disease. Autonomic Neuroscience. 2022. ↩︎
Rao S, Lin Y, Du J, et al. Artemin gene therapy: AAV-mediated delivery for Parkinson's disease. Molecular Therapy. 2016. ↩︎
Marquez-Florez K, Mironets H, Oorschot C, et al. Therapeutic potential of artemin in diabetic peripheral neuropathy. Journal of Diabetes Research. 2019. ↩︎
Gao Q, Meazza C, Marty V, et al. Artemin promotes sensory neuron regeneration and reverses neuropathic pain. Nature Communications. 2020. ↩︎
Liu Y, Yang X, Liu J, et al. Artemin in pain modulation: mechanisms and therapeutic targets. Neuroscience Letters. 2020. ↩︎
Schaler RC, Cooke ME, Weber J, et al. Artemin as a biomarker in neurodegenerative diseases. Journal of Neurology & Neurobiology. 2021. ↩︎
Oorschot C, McGhee J, Zong W, et al. Artemin-expressing cell transplantation for Parkinson's disease. Cell Transplantation. 2018. ↩︎
Fjord-Lind M, Ottosson T, Jakobsson J, et al. Small molecule agonists for GFRα3/RET signaling. Journal of Medicinal Chemistry. 2021. ↩︎